Navigation Links
Derma Sciences Enrolls First Patient in DSC127 Phase II Study
Date:11/3/2008

INITIATION OF 75-PATIENT STUDY ON DIABETIC FOOT ULCERS

PRINCETON, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI) announced today the first study patient has been entered into the company's Phase II study of its drug candidate, DSC127. Enrollment of the 75-patient study, looking into the drug's ability to accelerate healing in diabetic foot ulcers, is expected to be completed within 12 months. Currently, 4 US facilities have signed on as clinical study sites, with an additional 15 sites pending contract negotiations and internal review board approvals. All sites are based in the United States and include top-tier academic institutions and large, highly regarded wound care clinics. Derma Sciences acquired the global rights to the product and to the patent portfolio surrounding it - for wound care and scar prevention applications - in November, 2007.

Extensive pre-clinical studies have shown that DSC127 - a biologically active angiotensin analog - significantly increases wound healing rates, notably in reliable and validated diabetic animal models. Diabetic ulcerations represent a large and growing portion of the overall chronic wound care market. More than simply a blister on a patient's foot, non-healing diabetic foot ulcerations can lead to a cascade of events including infection, amputation of the patient's limb, and even death. In the United States alone, there are an estimated 2.4 million diabetic foot ulcers and over 60,000 diabetes-related amputations each year. Depending on the study, 5-year mortality rates following a diabetic ulcer related amputation have been shown to range from 39% to 68%. Ulcers are present in 3% to 6% of all hospital stays in which diabetes is listed on the discharge record. The average length of these hospital stays is 59% greater than stays in which diabetes is listed on the discharge record but when an ulceration is not present. In 2001, the financial costs to US healthcare
'/>"/>

SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
2. Dermatologists identify North Texas leishmaniasis outbreak
3. Tissue-Growth Gene Tied to Scleroderma
4. American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification (TAN) Act
5. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
6. VivaScope(R) Confocal Imager May Eliminate Need for Routine Skin Biopsies for Dermatology Patients
7. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
8. American Academy of Dermatology: New Study Finds Women More Likely Than Men to be Affected by Acne as Adults
9. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
10. Dermatologists Warn Fitness Enthusiasts: Dont Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity
11. Active compounds found in Ganoderma lucidum fungus with potential to treat prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... 19, 2013 According to a ... and Forecast (2013 – 2018): By Applications (Healthcare ... Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) And ... sensor market was $8.00 billion in 2012 and ... at an estimated CAGR of 3.84% from 2013 ...
(Date:5/19/2013)... 19, 2013 The Pradaxa lawyers at ... was recently convened for hundreds of Pradaxa bleeding ... underway in U.S. District Court, Southern District of Illinois. ... on May 14th, the Conference addressed the status of ... during the Conference that Defendants submitted a list of ...
(Date:5/19/2013)... Vegas, Nevada (PRWEB) May 19, 2013 ... agency , is proud to announce the launch it's ... Awards at the MGM Grand on 5/19/2013. Consumers traveling ... all new special pricing available on VegasHotelEscapes.com's website. Travelers ... that they beat any competitors price. , Vegas Hotel ...
(Date:5/19/2013)... Rockford, IL (PRWEB) May 19, 2013 Beginning ... Rock River Valley Blood Center (RRVBC) will feature “Hot Dog ... and Belvidere. RRVBC will provide hot dogs and all ... feature ice-cold slushies each day throughout the summer. “Donors are ... to maintain a stable and adequate blood supply. This ...
(Date:5/19/2013)... Raton, FL (PRWEB) May 19, 2013 ... launched the website YazSideEffects.com in a concerted effort to ... of the combination birth control drugs Yaz, Yasmin & ... offers a wealth of information on the notorious birth ... lawsuits against Bayer Pharmaceuticals. , Yaz, Yasmin & ...
Breaking Medicine News(10 mins):Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2
... and the good fats in Omega-3 fatty acids help new ... the issue of the International Breastfeeding Journal. ... affecting anywhere from 10 percent to 20 percent of postpartum ... as high as 40 percent or 50 percent. Since depression ...
... the home clearly raise the risk of the allergic sensitisation ... older children , however, the influence of the environment at ... This is the conclusion reached by scientists from the GSF ... ,The study published by Chih-Mei Chen et ...
... New Jersey The nations publicized gay governor, James E. McGreevy ... he has managed to be in the news for ... and has become an Episcopalian. ,Former Gov. James E. ... officially inducted into the Episcopal religion on Sunday at St. ...
... here have developed a device that can enable the blind to ... it costs Rs.2,000-3,000 and it reads texts through an embedded system ... ,Right now it can only read text, but ... ,The Agra College team that took six months to ...
... to the information furnished by Indira Gandhi National Open ... of Parliament/State legislature or deemed to be university ... of norms and guidelines laid down by the Distance ... its meeting held on March 23, 2007 had resolved ...
... state representatives from 105 countries met Friday to formally adopt ... impacts of global warming after five days of heated debate ... discussions ended at 3:30 a.m. Friday," said Carloa Traverso Saibante, ... (IPCC). ,Once the IPCC report is formally adopted, ...
Cached Medicine News:Health News:Breastfeeding and Omega-3 Fatty Acids Help New Moms Fight Depression 2Health News:Cats at Home Poses Allergy Risk in Young Children 2Health News:Climate Talks Reach Consensus in Bangkok 2
(Date:5/17/2013)... today announced that it will report its 2013 first quarter earnings on ... Ed Borkowski , CFO, will host an analyst and ... To participate in the conference call within the U.S. and ... conference call outside the U.S. and Canada , dial ... Participants should dial in 10 minutes prior to the start of the ...
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
(Date:5/17/2013)... , May 17, 2013 Oramed ... of oral drug delivery systems, announced today that the ... the Company,s Investigational New Drug application(IND) for ORMD-0801, its ... to have the FDA clearance to proceed," stated ... upcoming trial is a major milestone for Oramed and ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3
... Male Hypogonadism, LEXINGTON, Mass., Aug. 28 ... that it has submitted,a New Drug Application (NDA) ... approval for NEBIDO(R) (testosterone undecanoate) intramuscular,injection, a long-acting ... and secondary hypogonadism. Each 1000 mg injection of,NEBIDO ...
... Corporation,(Nasdaq: CRGN ) and TopoTarget A/S (Copenhagen ... dosing in a Phase I/II clinical,trial evaluating belinostat ... the anthracycline idarubicin for the,treatment of Acute Myeloid ... sites in the European Union. Patients under ...
Cached Medicine Technology:Indevus Announces Submission of New Drug Application 2Indevus Announces Submission of New Drug Application 3Indevus Announces Submission of New Drug Application 4Indevus Announces Submission of New Drug Application 5Indevus Announces Submission of New Drug Application 6CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 2CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 3CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 4CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 5CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 6
... Revolutions start with small things. The ... one of the trailblazers of the ... the,trend towards ever smaller access and ... operation site. ,The HiLAN XS motor ...
The stereotactic frame has been specifically designed for a radiosurgery procedure and can be used instead of traditional expensive frames....
The stereotactic frame has been specifically designed for a radiosurgery procedure and can be used instead of traditional expensive frames....
... The basic frame, consisting of one part only, ... fixations of highly compressed Polyamide may be rotated ... to all head sizes and shapes, as well. ... frame far enough in caudal direction, which is ...
Medicine Products: